DUBLIN, February 28, 2014 /PRNewswire/ --
Dublin - Research and Markets (http://www.researchandmarkets.com/research/xlfhdl/european) has announced the addition of the "Concise Analysis of the European Injectable Drug Delivery - Market Forecasts to 2017" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Injectable drug delivery technologies are a combination of two major segments - devices and formulations. The European injectable drug delivery formulations technologies market is the largest segment in the market. This is due to a surge of biologics and development of nanotechnologies. Based on product type, the injectable drug delivery devices technologies market is further categorized as conventional injection devices, self-injection devices, and others (microneedles, nanoneedles and blunt needle injections), while the injectable drug delivery formulation technologies market is categorized as conventional drug delivery formulations and novel drug delivery formulations. The conventional injection devices segment accounted for the largest share of the European injectable drug delivery technologies market in 2012.
The market is also segmented on the basis of its therapeutic applications as auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilsons disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Hormonal disorders commanded the largest share of the European injectable drug delivery technologies market in 2012.
The European injectable drug delivery technologies market has witnessed challenging and dynamic market conditions (due to technological advancements and surge of biologics and biosimilars in pharmaceutical market) over the last five years. Newer products with better safety and efficacy contribute to the widespread adoption of injectable drug delivery technologiesby physicians and patients. However, factors such as needle-stick injuries and infections and development of alternate delivery methods (oral, nasal and topical) for injectable drugs are restraining the growth of the market.
The key players in this market are Becton Dickinson & Co. (U.S.), Baxter International, Inc. (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Eli Lily & Co. (U.S.), Gerresheimer AG (Germany), Sanofi (France), West Pharmaceutical Services, Inc. (U.S.), Haselmeier GmbH (Germany), and Owen Mumford, Ltd. (U.K.).
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 European Injectable Drug Delivery Devices Technologies Market
5 European Injectable Drug Delivery Formulation Technologies Market
6 European Injectable Drug Delivery Technologies Market, By Therapeutic Applications
7 Geographic Analysis
8 Competitive Landscape
9 Company Profiles
- Bespak Europe
- Injex Pharma
- Novo Nordisk
- Owen Mumford
- Vetter Pharma-Fertigung Gmbh & Co
- Ypsomed Holding
For more information visit http://www.researchandmarkets.com/research/xlfhdl/european
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets